Kura Total Other Income Expense Net vs Research Development Analysis
| KURA Stock | USD 18.57 1.01 5.75% |
Kura Oncology financial indicator trend analysis is infinitely more than just investigating Kura Oncology recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Kura Oncology is a good investment. Please check the relationship between Kura Oncology Total Other Income Expense Net and its Research Development accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kura Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Kura Stock refer to our How to Trade Kura Stock guide.
Total Other Income Expense Net vs Research Development
Total Other Income Expense Net vs Research Development Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Kura Oncology Total Other Income Expense Net account and Research Development. At this time, the significance of the direction appears to have very strong relationship.
The correlation between Kura Oncology's Total Other Income Expense Net and Research Development is 0.86. Overlapping area represents the amount of variation of Total Other Income Expense Net that can explain the historical movement of Research Development in the same time period over historical financial statements of Kura Oncology, assuming nothing else is changed. The correlation between historical values of Kura Oncology's Total Other Income Expense Net and Research Development is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Other Income Expense Net of Kura Oncology are associated (or correlated) with its Research Development. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Research Development has no effect on the direction of Total Other Income Expense Net i.e., Kura Oncology's Total Other Income Expense Net and Research Development go up and down completely randomly.
Correlation Coefficient | 0.86 |
| Relationship Direction | Positive |
| Relationship Strength | Strong |
Total Other Income Expense Net
Research Development
Most indicators from Kura Oncology's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Kura Oncology current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kura Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Kura Stock refer to our How to Trade Kura Stock guide.At present, Kura Oncology's Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Issuance Of Capital Stock is expected to grow to about 155.6 M, whereas Enterprise Value Over EBITDA is forecasted to decline to (6.57).
Kura Oncology fundamental ratios Correlations
Click cells to compare fundamentals
Kura Oncology Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Kura Oncology fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 242.0M | 647.2M | 534.1M | 456.3M | 448.9M | 471.4M | |
| Total Stockholder Equity | (212.9M) | (302.5M) | (433.0M) | (568.8M) | 397.3M | 417.1M | |
| Net Debt | (18.6M) | (310.5M) | (83.8M) | (37.8M) | (20.1M) | (21.1M) | |
| Retained Earnings | (212.9M) | (302.5M) | (433.0M) | (568.8M) | (721.4M) | (685.4M) | |
| Cash | 26.1M | 325.5M | 90.7M | 51.8M | 37.3M | 40.2M | |
| Cash And Short Term Investments | 236.9M | 633.3M | 518.0M | 438.0M | 424.0M | 445.2M | |
| Liabilities And Stockholders Equity | (189.7M) | (266.2M) | (405.5M) | (532.8M) | 448.9M | 471.4M | |
| Other Stockholder Equity | (336K) | (53K) | 1.8M | 8.0M | 1.1B | 1.2B | |
| Total Current Assets | 239.6M | 637.3M | 522.3M | 446.4M | 432.5M | 454.1M | |
| Common Stock | 3K | 4K | 5K | 7K | 8.1K | 6.7K | |
| Total Current Liabilities | 15.6M | 26.0M | 22.5M | 24.1M | 35.3M | 37.0M | |
| Other Assets | 2.1M | 7.9M | 3.5M | 3.5M | 4.0M | 4.2M | |
| Common Stock Shares Outstanding | 41.9M | 53.1M | 66.4M | 67.0M | 73.2M | 76.9M | |
| Non Current Liabilities Total | 7.6M | 10.3M | 5.0M | 12.0M | 16.4M | 17.2M | |
| Total Liab | 23.2M | 36.3M | 27.4M | 36.0M | 51.7M | 54.2M | |
| Other Current Liab | 11.8M | 18.2M | 17.0M | 20.2M | 31.5M | 33.0M | |
| Accounts Payable | 3.5M | 2.8M | 3.2M | 1.5M | 2.3M | 1.9M | |
| Common Stock Total Equity | 3K | 4K | 5K | 7K | 8.1K | 8.5K | |
| Other Current Assets | 2.7M | 4.0M | 4.3M | 8.4M | 5.7M | 6.0M | |
| Net Tangible Assets | 218.8M | 610.9M | 506.6M | 420.3M | 483.3M | 507.5M | |
| Retained Earnings Total Equity | (212.9M) | (302.5M) | (433.0M) | (568.8M) | (511.9M) | (486.3M) | |
| Capital Surpluse | 431.3M | 913.4M | 941.4M | 997.1M | 1.1B | 1.2B | |
| Non Current Assets Total | 2.4M | 9.9M | 11.8M | 9.9M | 16.5M | 17.3M | |
| Non Currrent Assets Other | 2.3M | 1.4M | 3.3M | 3.3M | 7.4M | 7.8M | |
| Other Liab | 377K | 395K | 375K | 265K | 238.5K | 324.6K | |
| Long Term Debt | 7.5M | 7.3M | 4.3M | 9.2M | 9.3M | 7.1M | |
| Short Term Investments | 210.8M | 307.8M | 427.3M | 386.2M | 386.6M | 237.8M | |
| Accumulated Other Comprehensive Income | 331K | 46K | (1.8M) | (8.0M) | (1.3M) | (1.3M) | |
| Non Current Liabilities Other | 377K | 6.0M | 5.0M | 265K | 705K | 669.8K | |
| Long Term Debt Total | 7.5M | 7.3M | 4.3M | 9.2M | 10.5M | 7.5M | |
| Net Invested Capital | 226.3M | 618.2M | 506.6M | 429.4M | 406.6M | 383.8M | |
| Net Working Capital | 224.0M | 611.3M | 499.8M | 422.4M | 397.2M | 378.2M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Kura Oncology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Kura Oncology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Kura Oncology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Kura Oncology Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kura Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Kura Stock refer to our How to Trade Kura Stock guide.You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kura Oncology. If investors know Kura will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kura Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.35) | Return On Assets (0.29) | Return On Equity (0.46) |
The market value of Kura Oncology is measured differently than its book value, which is the value of Kura that is recorded on the company's balance sheet. Investors also form their own opinion of Kura Oncology's value that differs from its market value or its book value, called intrinsic value, which is Kura Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kura Oncology's market value can be influenced by many factors that don't directly affect Kura Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kura Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Kura Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kura Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.